Condition: Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · mCRPC · Sponsor: Blue Earth Therapeutics Ltd
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
This description comes directly from the study's public registry record.
Blue Earth Therapeutics · +44 (0)1865 634500 · contact@blueearthTx.com
Always discuss trial participation with your own doctor first.
| Biogenix Molecular LLC | Miami, Florida, United States | Recruiting |
| NovaCure Health | Miami, Florida, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| XCancer Omaha / Urology Cancer Center | Omaha, Nebraska, United States | Recruiting |
| Weill Cornell Medicine - New York - Presbyterian Hospital | New York, New York, United States | Completed |
| Saint Luc University Hospital | Brussels, Belgium | Recruiting |
| University Hospital Ghent | Ghent, Belgium | Recruiting |
| University Hospital Leuven | Leuven, Belgium | Recruiting |
| University Hospital Aachen | Aachen, Germany | Recruiting |
| Universitätsklinikum Augsburg | Augsburg, Germany | Recruiting |
| University Hospital Essen | Essen, Germany | Recruiting |
| Hospital Rechts der Isar | Munich, Germany | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05413850